- Avista Pharma Solutions Inc., a Durham, North Carolina-based CDMO, can now boast twice as much API manufacturing capacity at its Colorado facility after completing an expansion.
- Three existing GMP drug substance manufacturing suites have been upgraded and a fourth added to boost the plant's production capabilities. Two non-GMP development suites were also installed.
- "Our investments in suite upgrades and capacity expansion in Longmont have transformed the site into a world-class API manufacturing facility," said Ken Domagalski, general manager of the site, in a Nov. 13 statement.
Expansion at Longmont comes amid a broader build-out of Avista's manufacturing and testing capacity.
In March, Avista completed a $4 million upgrade of its contract testing facility in Agawam, Massachusetts. The site now covers an additional 4,200 square feet, including a microbiology laboratory and new cleanroom.
On the laboratory side, the CDMO has also improved its analytical laboratories located at its Durham, North Carolina headquarters.
Durham, Longmont and Agawam are Avista's three operating sites after it sold off its Egan, Minnesota-based facility to Microbiology Research Associates last fall.
Avista is owned by Ampersand Capital Partners, a private equity company based in Wellesley, Massachusetts, that hold stakes in a number of contract manufacturers, including Brammer Bio LLC.